Immune Therapeutics Inc. IMUN Archives

WednesdayApr 27, 2016 3:39 pm

Immune Therapeutics, Inc. (IMUN) Granted Approval for Lodonal™ in Nigeria

Earlier today, Immune Therapeutics, Inc. (OTCQB: IMUN) announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has approved the company’s patented Lodonal™ as an over-the-counter, non-toxic adjunct therapy in the treatment of HIV/AIDS. With this approval, IMUN’s distribution partners, AHAR Pharma and GB Pharma Holdings, will now be able to launch nationwide marketing and sales programs for the breakthrough immunotherapy, creating a new revenue stream for IMUN and contributing to health security in Nigeria. “Receiving approval of our affordable non-toxic immunodeficiency treatment Lodonal is a significant company milestone,” Noreen Griffin, chief executive officer of IMUN, stated…

ThursdayApr 21, 2016 11:52 am

Immune Therapeutics, Inc. (IMUN) Enters Binding Letter of Intent to Acquire Innovative CAR-T Cell Technology

Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced its entry into a binding letter of intent to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, pending immuno-oncology patents, manufacturing technology and clinical data regarding the aforementioned therapies from Super-T Cell Cancer Company (STCC), a newly-formed corporation. The technology outlined in this letter of intent could play a key role in IMUN’s ongoing efforts to achieve commercial approval for its patented immunotherapies, as described by Christopher Pearce, the company’s chief operating officer, in this morning’s news release: “This CAR-T cell technology licensing further accelerates IMUN's growth…

MondayApr 11, 2016 11:56 am

Immune Therapeutics, Inc. (IMUN) Offers Update on Methionine-Enkelphine Drug Development Program in China

Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) offered shareholders an update of the status of its ongoing drug development program in China. Recently, Chinese Peptide Company (CPC), one of only a handful of companies in the world that can claim both ISO Certification and cGMP licensing, completed the formulation and required Chemistry, Manufacturing and Controls (CMC) for Methionine-Enkelphine (MENK). IMUN’s long-term partner, Hubei Qianjiang Pharmaceutical Co. Ltd. (Qianjiang), is expected to provide formulation and CMC data to Cytocom, Inc., a subsidiary of IMUN, within 30 days. With this data in hand, Cytocom will take the necessary steps to…

WednesdayMar 30, 2016 11:46 am

Immune Therapeutics, Inc. (IMUN) Steadfast in Efforts Leveraging the Body’s Immune System on Continent of Africa

Immune Therapeutics, Inc. (OTCQB: IMUN) is positioned as a specialty pharmaceutical company focused on manufacturing, marketing and distributing novel patented therapies to fight chronic, life-threatening diseases. The company achieves this by way of the activation and modulation of the body’s immune system. Immune Therapeutics’ technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). These therapies have required decades to develop thanks to work at institutions like the Pennsylvania State University Medical School at Hershey, the State University of New York, the University of Chicago, and the Multiple Sclerosis Center at UCSF. Spearheading efforts at…

WednesdayMar 23, 2016 3:06 pm

Immune Therapeutics’ (IMUN) Lodonal Armors Africa against AIDS

Thought to have originated in Africa, the acquired immunodeficiency syndrome (AIDS) has undoubtedly become a scourge of the continent, particularly south of the Sahara. According to AVERT, the U.K.-based international charity, in sub-Saharan Africa, 24.7 million people, or about 4.7% of the continental population, were living with the human immunodeficiency virus (HIV) in 2013, the last year for which data is available. Over one million of those individuals have died every year since. South Africa, with 5.9 million, has the highest number of infected persons. Swaziland’s HIV infection rate of 27.4% (2013) is the highest worldwide. In Nigeria, although the…

ThursdayMar 17, 2016 1:20 pm

Immune Therapeutics, Inc. (IMUN) Armed with Expertise in the Immune System to Fight Infectious Diseases

Immune Therapeutics, Inc. (OTCQB: IMUN) centers its works on applying its patented immunotherapy to fight chronic diseases, such as cancer, which affect people of all ages and races all over the world. Leveraging the body’s natural immune system, the company’s product line and immunotherapy technologies are engineered to enhance treatment for those suffering with HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases. One of IMUN’s promising treatments is Low Dose Naltrexone (LDN), or Lodonal, as it is known on a global scale. Lodonal has its origins in the FDA-approved 50mg Naltrexone. Initially known to treat opiate dependencies, the…

ThursdayMar 10, 2016 9:42 am

Immune Therapeutics, Inc. (IMUN) Using the Power of the Body to Fight Cancer & AIDS

Cancer is the most serious disease in the history of mankind. All families in the U.S. and the world are affected by cancer either directly or indirectly. Men, women, and children of all races, creeds, and religions risk the possibility of being diagnosed with cancer – it does not discriminate. Some startling estimates for 2016 from the American Cancer Society are as follows: 841,390 new cancer cases in males in the U.S.; 843,820 new cancer cases in females in the U.S.; 314,290 deaths from cancer in males in the U.S.; and 281,400 deaths from cancer in females in the U.S.…

TuesdayMar 08, 2016 9:49 am

Immune Therapeutics, Inc. (IMUN) Bolsters Board of Directors with Addition of Selsky and Akin

Immune Therapeutics, Inc. (OTCQB: IMUN) made two additions to its board recently, and if experience and knowledge are said to be key indicators of effectiveness, employees and shareholders alike have reason to be elated with the news. Dr. Clifford A. Selsky and Paul Akin carry a wealth of experience in their respective areas of influence and bolster the company’s leadership assets going forward. Paul Akin brings financial experience developed across his prior operating and board roles to the IMUN board. Dr. Selsky offers a vital perspective as a scientist, physician and patient advocate. The company intends to use their respective…

ThursdayMar 03, 2016 10:47 am

Immune Therapeutics, Inc. (IMUN) Expands Board of Directors

Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced the appointment of two new members to its board of directors: Dr. Clifford A. Selsky and Paul Akin. Akin brings a wealth of financial experience developed across his prior operating and board roles to the Immune Therapeutics board, while Selsky offers a critical perspective as a scientist, physician and patient advocate. The company will look to leverage this combined experience as it continues to pursue sustainable financial growth by developing and commercializing novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system,…

FridayFeb 26, 2016 3:34 pm

Immune Therapeutics, Inc. (IMUN) Fighting the ‘War on Cancer’ With Immunotherapy

Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done in a couple of ways, including stimulating your own immune system to work harder or smarter to attack cancer cells or giving your immune system components, such as man-made immune system proteins. Some types of immunotherapy are also sometimes called biologic therapy or biotherapy. Immune Therapeutics, Inc. (OTCQB: IMUN) is a specialty pharmaceutical company involved in the manufacture, distribution and marketing of its novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the…

Site Search

Company Search

Tag: Immune Therapeutics Inc. IMUN